Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4467499 | 0.99 | MAOB (0.48) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4468926 | 0.93 | MAOB (0.49) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4460021 | 0.89 | MAOB (0.52) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4472466 | 0.89 | MAOB (0.52) | MAOBBACE1NPY5RCLK4PTGDR2 | |
| SCHEMBL4480647 | 0.87 | MAOB (0.48) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4476587 | 0.86 | MAOB (0.47) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4479177 | 0.86 | NPY5R (0.57) | MAOBBACE1NPY5RCLK4GABRG2 | |
| SCHEMBL4474803 | 0.86 | MAOB (0.49) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4467945 | 0.86 | MAOB (0.49) | MAOBBACE1NPY5RCLK4GABRA1 | |
| SCHEMBL4468764 | 0.85 | MAOB (0.46) | MAOBBACE1NPY5RCLK4GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064142-B2 | Imidazonline compounds | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | claimed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | claimed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | claimed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060135559-A1 | Novel imidazoline compounds | MSD K.K. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-7064142-B2 | Imidazonline compounds | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135559-A1 | Novel imidazoline compounds | GPR119, NPY1R, NPY2R | MAOB 1890/4885BACE1 864/4885NPY5R 9/4885 |
| US-20030158418-A1 | Novel imidazonline compounds | NPY1R, NPY2R, GPR119 | MAOB 1639/4885BACE1 510/4885NPY5R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.